At what enterprise value was D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) acquired in 2019?

During the acquisition of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) by EURAZEO in 2019, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) when it was acquired by EURAZEO?

The exact EV/EBITDA multiple for D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) at the time of the deal?

The revenue of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://fr.newsroom.eurazeo.com/assets/2019-04-25-dorc-fr-v06-pdf-f4870-7ed35.html

← DATABASE

Home Database Healthcare & PharmaD.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)

04/2019

D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) acquired by EURAZEO

NETHERLANDS Life Sciences / Medical Devices EV 300M - 700M EUR

Context

Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market. The strategic plan focuses on capitalizing on D.O.R.C.'s highly regarded brand and innovative technology to drive further international growth, with a specific priority on capturing market share in the US. Eurazeo also intends to support the company's shift towards a higher mix of recurring revenue through its proprietary consumables and surgical packs.

D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER), which reported an EBITDA margin of LOGIN in 2018, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in the Netherlands, D.O.R.C. is a global leader in ophthalmic surgery equipment. It specializes in the "posterior segment" of the eye (vitreoretinal surgery). Its flagship product, the EVA Nexus platform, is a dual-function system used for both cataract and retina surgeries, highly regarded by surgeons for its precision.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2018

2017

Other operations with D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
08/2023	CARL ZEISS MEDITEC	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Life Sciences	Eurazeo has completed the sale of D.O.R.C. to Carl Zeiss Meditec AG. This transaction marks the successful conclusion of a four-year transformation under Eurazeo's ownership, during which D.O.R.C. evolved from a European champion into a global platform

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) by EURAZEO are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: eurazeo